Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emapticap pegol - TME Pharma

Next Previous
Drug Profile

Emapticap pegol - TME Pharma

Alternative Names: NOX-E36

Latest Information Update: 07 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NOXXON Pharma AG
  • Developer Singapore Eye Research Institute; TME Pharma
  • Class Amides; Antineoplastics; Eye disorder therapies; Nucleotide aptamers; Polyethylene glycols; Small molecules
  • Mechanism of Action Chemokine CCL2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Eye disorders
  • Discontinued Diabetic nephropathies; Solid tumours

Most Recent Events

  • 05 Jan 2026 Emapticap pegol is available for licensing as of 05 Jan 2026
  • 05 Nov 2025 Preclinical trials in Eye disorders in Singapore (unspecified route) prior to November 2025
  • 18 Jun 2025 TME Pharma terminates its collaboration agreement with Singapore Eye Research Institute for emapticap pegol

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top